Holen Sie sich die Stockscreener-App
45.46
2.57%
-1.20
Schlusskurs vom Vortag:
$46.66
Offen:
$46.47
24-Stunden-Volumen:
415.08K
Relative Volume:
0.51
Marktkapitalisierung:
$2.55B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
42.50
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
-1.17%
1M Leistung:
+10.23%
6M Leistung:
+44.87%
1J Leistung:
+47.12%
1-Tages-Spanne:
$45.39
$46.67
1-Wochen-Bereich:
$45.26
$46.78
52-Wochen-Spanne:
$29.16
$46.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.46 | 2.59B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - MSN
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - Yahoo Finance
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Published on: 2025-09-08 10:08:24 - beatles.ru
Will Supernus Pharmaceuticals Inc. benefit from rising consumer demandPortfolio Return Summary & High Conviction Buy Zone Picks - خودرو بانک
Stock Analysis: Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Outlook & Daily Chart Pattern Signal Reports - خودرو بانک
How to use a screener to detect Supernus Pharmaceuticals Inc. breakouts2025 Sector Review & AI Based Buy/Sell Signal Reports - Newser
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesEarnings Recap Summary & Precise Buy Zone Tips - خودرو بانک
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Price Targets & Free Community Supported Trade Ideas - خودرو بانک
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsMarket Trend Review & Daily Stock Momentum Reports - Newser
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Gainers & AI Driven Stock Movement Reports - خودرو بانک
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.July 2025 Sentiment & Weekly Breakout Stock Alerts - Newser
What’s the beta of Supernus Pharmaceuticals Inc. stockMarket Trend Report & Weekly Return Optimization Alerts - خودرو بانک
Has Supernus Pharmaceuticals Inc. found a price floorWeekly Profit Summary & Daily Chart Pattern Signals - Newser
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 PreEarnings & Real-Time Price Movement Reports - Newser
Supernus at Wells Fargo Conference: Strategic Growth in CNS By Investing.com - Investing.com Canada
Will Supernus Pharmaceuticals Inc. benefit from geopolitical trends2025 Investor Takeaways & Low Risk Growth Stock Ideas - خودرو بانک
Published on: 2025-09-04 06:09:28 - Newser
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesMarket Risk Analysis & Long-Term Safe Investment Ideas - Newser
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - خودرو بانک
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com Canada
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Will Supernus Pharmaceuticals Inc. stock recover after earnings2025 Market Overview & Low Risk Profit Maximizing Plans - خودرو بانک
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
What hedge funds are buying Supernus Pharmaceuticals Inc.July 2025 Decliners & AI Driven Price Forecasts - خودرو بانک
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - خودرو بانک
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - خودرو بانک
What are Supernus Pharmaceuticals Inc.’s earnings expectationsWeekly Risk Report & Stepwise Trade Execution Plans - خودرو بانک
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Sep 08 '25 |
Option Exercise |
25.30 |
8,074 |
204,272 |
1,118,305 |
| Khattar Jack A. | President, CEO |
Sep 08 '25 |
Sale |
46.29 |
6,322 |
292,645 |
1,111,983 |
| Khattar Jack A. | President, CEO |
Sep 05 '25 |
Option Exercise |
25.30 |
73,176 |
1,851,353 |
1,165,809 |
| Khattar Jack A. | President, CEO |
Sep 05 '25 |
Sale |
46.01 |
55,578 |
2,557,144 |
1,110,231 |
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):